(Q35056870)

6 August 2017

1 reference

title

Nanofiltration of plasma-derived biopharmaceutical products (English)

1 reference

6 August 2017

Burnouf T

1

1 reference

6 August 2017

Radosevich M

series ordinal

2

1 reference

6 August 2017

publication date

1 January 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

24-37

1 reference

Reducing the risk of infection from plasma products: specific preventative strategies

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Human parvovirus B19 and blood products

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Hepatitis A virus infections associated with clotting factor concentrate in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Membrane separations in biotechnology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Inactivation and clearance of viruses during the manufacture of high purity factor IX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Chromatography in plasma fractionation: benefits and future trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Affinity chromatography in the industrial purification of plasma proteins for therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Large-scale screening for human parvovirus B19 DNA by PCR: application to the quality control of plasma for fractionation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

A therapeutic, highly purified factor XI concentrate from human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Development of a pharmaceutical apotransferrin product for iron binding therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Development of a highly purified multicomponent leukocyte IFN-alpha product

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Risk of variant Creuzfeldt-Jakob disease from factor concentrates: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Accumulation of prion protein in tonsil and appendix: review of tissue samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

Scrapie removal using Planova virus removal filters

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2516.2003.00701.X

10.1046/J.1365-2516.2003.00701.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference